SCHEMBL360398

SCHEMBL360398

CCn1cc(-n2ccc(=O)c(OC(C)c3ccc4nccc(OC)c4c3)n2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 15/20 0.38
PDGFRB P09619 10/20 0.38
KDR P35968 7/20 0.38
FLT3 P36888 6/20 0.36
FLT4 P35916 3/20 0.36
PIK3CG P48736 2/20 0.34
ABL1 P00519 5/20 0.34
LYN P07948 5/20 0.34
TGFBR1 P36897 5/20 0.34
TGFBR2 P37173 5/20 0.34
SIK1 P57059 5/20 0.34
SIK2 Q9H0K1 5/20 0.34
SIK3 Q9Y2K2 5/20 0.34
PRKAB2 O43741 3/20 0.34
PRKAG1 P54619 3/20 0.34
PRKAA1 Q13131 3/20 0.34
SYK P43405 1/20 0.33
MET P08581 1/20 0.32
HDAC1 Q13547 1/20 0.32
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359822 0.89 MET (0.36) CSF1RPDGFRBKDRPIK3CGSYK
SCHEMBL358937 0.73 MET (0.37) CSF1RPDGFRBKDRFLT3PIK3CG
SCHEMBL14915679 0.73 MET (0.52) ABL1MET
SCHEMBL359518 0.73 MET (0.52) ABL1MET
SCHEMBL361252 0.71 MET (0.43) MET
SCHEMBL10283428 0.71 FGFR2 (0.32)
SCHEMBL359990 0.70 MET (0.37) KDRMET
SCHEMBL360670 0.69 MET (0.44) SYKMET
SCHEMBL368067 0.69 MET (0.39) CSF1RPDGFRBKDRFLT3FLT4
SCHEMBL10283429 0.68 MET (0.44) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET CSF1R 526/4885PDGFRB 64/4885KDR 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.